Prevention of type I diabetes in the non-obese diabetic (NOD) mouse with 15-deoxyspergualin (15-DS) or 15-DS + cyclosporin A (CyA)

J Haberstroh; T Wilhelm; J Schulte-Mönting; H U Schorlemmer; B U von Specht

doi:10.1016/0165-2478(95)02454-9

Prevention of type I diabetes in the non-obese diabetic (NOD) mouse with 15-deoxyspergualin (15-DS) or 15-DS + cyclosporin A (CyA)

Immunol Lett. 1995 Dec;48(2):117-21. doi: 10.1016/0165-2478(95)02454-9.

Authors

J Haberstroh¹, T Wilhelm, J Schulte-Mönting, H U Schorlemmer, B U von Specht

Affiliation

¹ Chirurgische Universitätsklinik, Freiburg, Germany.

PMID: 8719109
DOI: 10.1016/0165-2478(95)02454-9

Abstract

By selectively inbreeding diabetic individuals, we have been able to establish an NOD mouse population with a genetic predisposition towards insulin-dependent diabetes mellitus (IDDM) in approximately 100% of cases. We examined the preventive effect of 15-DS or 15DS + CyA on developing IDDM in these animals. Whereas 15-DS has been proved to be effective in preventing diabetes (significant decrease of the diabetic risk ratio to 0.368 and a reduction of the incidence of the disease to 46.7%), combined treatment with CyA did not produce any additional benefit.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cyclosporine / pharmacology*
Cyclosporine / therapeutic use
Diabetes Mellitus, Type 1 / immunology
Diabetes Mellitus, Type 1 / prevention & control*
Drug Therapy, Combination
Female
Guanidines / pharmacology*
Guanidines / therapeutic use
Hypoglycemic Agents / pharmacology*
Hypoglycemic Agents / therapeutic use
Immunosuppressive Agents / pharmacology
Male
Mice
Mice, Inbred NOD
Random Allocation

Substances

Guanidines
Hypoglycemic Agents
Immunosuppressive Agents
Cyclosporine
gusperimus